T0	Participants 213 261	patients with bone marrow transplantation (BMT).
T1	Participants 322 346	patients undergoing BMT.
T2	Participants 385 465	66 patients with 43 hematologic and 23 solid malignancies (21 breast carcinomas)
T3	Participants 761 799	Patients with hematologic malignancies
T4	Participants 956 997	Patients with solid malignancies (n = 23)
T5	Participants 1032 1097	14 in-hospital deaths without relationship to GLN administration.
T6	Participants 1463 1505	1 of 10 hematologic patients receiving GLN